LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$1.21
-0.04 (-3.20%)
Open$1.26
Previous Close$1.25
Day High$1.29
Day Low$1.21
52W High$2.09
52W Low$0.83
Volume—
Avg Volume1.28M
Market Cap301.65M
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+3,240.5% upside
Current
$1.21
$1.21
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.60M | 7.82M | 231.61M |
| Net Income | -67,165,987 | -37,518,240 | -65,233,876 |
| Profit Margin | -240.2% | -228.2% | -28.2% |
| EBITDA | -37,973,961 | -22,390,307 | -95,106,936 |
| Free Cash Flow | — | — | -33,113,271 |
| Rev Growth | +61.1% | +61.1% | -6.2% |
| Debt/Equity | 0.00 | 0.00 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |